Has Vasant Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $903 in general payments to Vasant Patel, MD across 48 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vasant Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vasant Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vasant Patel, MD

Geriatric Medicine · North Reading, MANPI 1811900442

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $697 and has fallen 90.7% since, to $65 in 2024.

$903in general payments, 2019–2025

Across 48 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$189
Novartis$121
Pfizer$119
AstraZeneca$113
Johnson & Johnson$101
E.r. Squibb & Sons, L.L.C.$82
plus $178 from 7 others

What the payments were for

Food & beverage$903100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	8	$189
Novartis	8	$121
Pfizer	7	$119
AstraZeneca	6	$113
Johnson & Johnson	5	$101
E.r. Squibb & Sons, L.L.C.	4	$82
Amarin Pharma, Inc.	4	$75
Kiniksa Pharmaceuticals International, PLC	1	$24
Edwards Lifesciences	1	$20
Mylan Specialty L.p.	1	$18
Kyowa Kirin, Inc.	1	$15
Boehringer Ingelheim	1	$13
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$12

How this compares

$903 in reported general payments places this provider in the 85th percentile of 156 geriatric medicine providers in Massachusetts.

See all geriatric medicine providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$171,517

Medicare patients

372

Services billed

1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	168	$216,936
XareltoRivaroxaban	36	$46,061
JardianceEmpagliflozin	24	$27,779
Atorvastatin Calcium	928	$13,588
Metoprolol Succinate	505	$10,105
Levothyroxine Sodium	312	$4,073
Ezetimibe	59	$3,719
SynthroidLevothyroxine Sodium	42	$3,697
Lisinopril	414	$3,605
Amlodipine Besylate	448	$3,513
Mesalamine DrMesalamine	23	$3,177
Losartan Potassium	213	$2,752
Omeprazole	171	$2,545
Wixela InhubFluticasone Propion/Salmeterol	13	$2,473
Niacin ErNiacin	13	$2,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$119	$216,936168 claims
Johnson & JohnsonXarelto	$101	$46,06136 claims
Boehringer IngelheimJardiance	$13	$27,77924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 geriatric medicine providers in Massachusetts.